Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity - PubMed (original) (raw)
Clinical Trial
Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity
Chao-Hua Chiu et al. Lung Cancer. 2005 Jan.
Abstract
Gefitinib is active and well tolerated in patients with advanced non-small cell lung cancer (NSCLC); however, its role in patients with brain metastases has not been clearly defined. We had conducted a prospective study to give gefitinib to NSCLC patients irrespective of their performance status (PS), number of prior treatment regimens and the presence of brain metastases. A total of 76 patients were enrolled. Fifty-seven patients had measurable lesions and the objective response rate was 33.3% (95% confidence interval [95% CI], 20.7-46.0%). For all enrolled patients, the disease control rate was 63.2% (95% CI, 52.1-74.3%) with a median progression-free survival of 5.0 months (95% CI, 3.6-6.5 months) and median overall survival 9.9 months (95% CI, 4.9-14.8 months). Twenty-one patients had simultaneously assessable intracranial lesions (ICLs) and extracranial lesions (ECLs), 17 of them (81.0%) showed comparable tumor response. There was no survival difference between the patients with and without metastatic brain disease. Most drug-related adverse events were mild. Intolerable toxicities happened in five patients, four of them were interstitial pneumonia (5.8%). Severity of skin toxicity was tightly associated with tumor response and patient survival (P = 0.007 and <0.001) and the association was consistent in the analysis using early toxicity profile (P = 0.033 and 0.001). In conclusion, gefitinib is active in patients with brain metastasis from NSCLC and tumor response is related to skin toxicity. It is feasible to conduct randomized trials to identify the role of gefitinib alone or in combination with other modality for treatment of NSCLC patients who have metastatic brain lesion(s).
Similar articles
- Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.
Hotta K, Kiura K, Ueoka H, Tabata M, Fujiwara K, Kozuki T, Okada T, Hisamoto A, Tanimoto M. Hotta K, et al. Lung Cancer. 2004 Nov;46(2):255-61. doi: 10.1016/j.lungcan.2004.04.036. Lung Cancer. 2004. PMID: 15474674 Clinical Trial. - [Gefitinib is active in patients with brain metastasis from non-small cell lung cancer].
Tsai C, Chiu C, Liou J, Tsai P, Perng R. Tsai C, et al. Zhongguo Fei Ai Za Zhi. 2004 Aug 20;7(4):298-304. doi: 10.3779/j.issn.1009-3419.2004.04.07. Zhongguo Fei Ai Za Zhi. 2004. PMID: 21241546 Chinese. - Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases.
Namba Y, Kijima T, Yokota S, Niinaka M, Kawamura S, Iwasaki T, Takeda Y, Kimura H, Okada T, Yamaguchi T, Nakagawa M, Okumura Y, Maeda H, Ito M. Namba Y, et al. Clin Lung Cancer. 2004 Sep;6(2):123-8. doi: 10.3816/CLC.2004.n.026. Clin Lung Cancer. 2004. PMID: 15476598 Review. - A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer.
Park K, Goto K. Park K, et al. Curr Med Res Opin. 2006 Mar;22(3):561-73. doi: 10.1185/030079906X89847. Curr Med Res Opin. 2006. PMID: 16574039 Review.
Cited by
- Characteristics of patients with brain metastases from lung cancer in a palliative care center.
Yamanaka R, Koga H, Yamamoto Y, Yamada S, Sano T, Fukushige T. Yamanaka R, et al. Support Care Cancer. 2011 Apr;19(4):467-73. doi: 10.1007/s00520-010-0838-5. Epub 2010 Mar 10. Support Care Cancer. 2011. PMID: 20217148 - Upfront Advanced Radiotherapy and New Drugs for NSCLC Patients with Synchronous Brain Metastases: Is the Juice Worth the Squeeze? A Real-World Analysis from Lombardy, Italy.
Corrao G, Franchi M, Zaffaroni M, Vincini MG, de Marinis F, Spaggiari L, Orecchia R, Marvaso G, Jereczek-Fossa BA. Corrao G, et al. Cancers (Basel). 2023 Feb 9;15(4):1103. doi: 10.3390/cancers15041103. Cancers (Basel). 2023. PMID: 36831447 Free PMC article. - Current management of metastatic brain disease.
Ranjan T, Abrey LE. Ranjan T, et al. Neurotherapeutics. 2009 Jul;6(3):598-603. doi: 10.1016/j.nurt.2009.04.012. Neurotherapeutics. 2009. PMID: 19560748 Free PMC article. Review. - The Efficacy of Postoperative Chemotherapy for Patients with Metastatic Brain Tumors from Non-Small Cell Lung Cancer.
Hong N, Joo JN, Shin SH, Gwak HS, Lee SH, Yoo H. Hong N, et al. Brain Tumor Res Treat. 2015 Oct;3(2):108-14. doi: 10.14791/btrt.2015.3.2.108. Epub 2015 Oct 30. Brain Tumor Res Treat. 2015. PMID: 26605266 Free PMC article. - Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer.
Byrne BJ, Garst J. Byrne BJ, et al. Curr Oncol Rep. 2005 Jul;7(4):241-7. doi: 10.1007/s11912-005-0045-6. Curr Oncol Rep. 2005. PMID: 15946581 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical